(Reuters) – British drugmaker GSK Plc said on Monday its blood cancer drug Blenrep failed the main goal of a late-stage study designed to show that the treatment was better than the standard of care on the market.
GSK said Blenrep did not meet its primary endpoint of progression-free survival when compared with pomalidomide in combination with low dose dexamethasone in the superiority trial called DREAMM-3.
(Reporting by Amna Karimi and Pushkala Aripaka in Bengaluru; Editing by Rashmi Aich)
